4 results
• Determine the maximum tolerated dose (MTD) and/or recommended dose (RD) for further evaluation of XL092 when administered alone and in combination with ICIs to subjects with advanced solid tumors• Evaluate preliminary efficacy of XL092 when…
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)
This study will evaluate the efficacy and safety of multiple therapies that are selected using somatic alterations and potential predictive biomarkers identified via NGS assays in patients with solid tumors:
The aim of the present study is to determine the effectiveness of the RISE intervention on reducing sedentary behavior after discharge from acute hospital care in community dwelling people with a stroke, who have a sedentary movement behavioral…